Table 3.
Musculoskeletal pain and baseline, 6-month, and change in IGF-I, IGFBP3, and IGF1:IGFBP3 ratio concentrations among women with breast cancer patients initiating aromatase inhibitor therapy and women in the comparison group
| Women with breast cancer
|
||||||
|---|---|---|---|---|---|---|
| Baseline
|
6-months
|
% change (range) | p-value b | |||
| n | mean (SD) | n | mean (SD) | |||
|
| ||||||
| IGF-1 (ng/mL) | ||||||
| New or increase in pain | 41 | 123.6 (34.1) | 41 | 132.6 (41.9) | 7.3 (−31.0 to 178.9) | 0.1 |
| No new or increase in pain | 11 | 152.3 (49.9) | 11 | 138.3 (46.4) | −9.2 (−24.9 to 8.4) | 0.009 |
| p-value | 0.097a | 0.7a | 0.048c | |||
| IGFBP-3 (ng/mL) | ||||||
| New or increase in pain | 41 | 4206.4 (976.2) | 41 | 4333.4 (1093.5) | 3.0 (−25.2 to 107.2) | 0.3 |
| No new or increase in pain | 11 | 4388.3 (1052.9) | 11 | 4819.6 (1224.6) | 9.8 (−14.5 to 48.0) | 0.09 |
| p-value | 0.6a | 0.3a | 0.3c | |||
| IGF-1: IGFBP-3 ratio | ||||||
| New or increase in pain | 41 | 0.030 (0.01) | 41 | 0.031 (0.01) | 3.8 (−31.0 to 85.9) | 0.2 |
| No new or increase in pain | 11 | 0.035 (0.01) | 11 | 0.029 (0.01) | −16.7 (−30.8 to 14.0) | 0.005 |
| p-value | 0.092a | 0.4a | 0.001c | |||
| Women in the comparison group
|
||||||
|---|---|---|---|---|---|---|
| Baseline
|
6-months
|
% change (range) | p-valueb | |||
| n | mean (SD) | n | mean (SD) | |||
|
| ||||||
| IGF-1 (ng/mL) | ||||||
| New or increase in pain | 49 | 122.9 (35.8) | 49 | 124.3 (31.7) | 1.1 (−25.9 to 114.3) | 0.6 |
| No new or increase in pain | 39 | 122.5 (35.8) | 39 | 122.4 (28.7) | 0.01 (−25.4 to 59.2) | 1.0 |
| p-value | 1.0a | 0.8a | 0.2c | |||
| IGFBP-3 (ng/mL) | ||||||
| New or increase in pain | 49 | 4179.8 (806.0) | 49 | 4203.5 (716.8) | 0.6 (−16.1 to 67.8) | 0.7 |
| No new or increase in pain | 39 | 4392.0 (901.7) | 39 | 4250.8 (755.4) | −3.2 (−34.9 to 57.0) | 0.2 |
| p-value | 0.3a | 0.8a | 0.7c | |||
| IGF-1: IGFBP-3 ratio | ||||||
| New or increase in pain | 49 | 0.029 (0.01) | 49 | 0.030 (0.01) | 1.6 (−29.2 to 32.0) | 0.5 |
| No new or increase in pain | 39 | 0.028 (0.01) | 39 | 0.029 (0.01) | 2.8 (−19.6 to 41.3) | 0.3 |
| p-value | 0.5a | 0.6a | 0.7c | |||
a
Independent samples t-test for mean differences between women who report new or increase in pain compared to no new or increase in pain
b
Paired t-test for mean differences between baseline and 6-month follow-up
c
Independent samples t-test for mean change differences between women who report new or increase in pain compared to no new or increase in pain